

T1D Companies Landscape - DRAFT

Company OniX Summary

Seraxis

Assets

Seraxis's assets are its intellectual property, specifically its proprietary stem cell line and its differentiation protocol for creating islets [1]. These islets mimic those found in a healthy pancreas and secrete insulin in response to blood sugar levels [1]. Additionally, Seraxis has an implantable biocompatible device, called SeraGraft, which protects the transplanted islets from the body's immune system.

MoA

The browsing extension could not find the specific mechanism of action (MoA) by which Seraxis islets function.

Stage of development

The document says that Seraxis islets have been successfully transplanted into animal models and reversed diabetes for over 9 months [1]. This suggests that Seraxis is in the pre-clinical stages of development. However, the document does not mention any human trial.

Indication

Seraxis is a regenerative medicine therapy for insulin-dependent diabetes [1]. It works by replacing damaged pancreatic cells with lab-grown cells. These cells are encapsulated in a device to protect them from the body's immune system.

Other indications

The content of the given URL did not provide any information on other indications for Seraxis.

Zucara

Asset

The document says that ZT-01 is the company's asset.

MoA (Mechanism of action)

ZT-01 works by inhibiting somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with insulin dependent diabetes [1]. This approach could dramatically change diabetes disease management and improve both patient health and quality of life.

Specifically, ZT-01 blocks somatostatin type 2 (SSTR2) receptors on α -cells in the pancreas, which are stimulated at a higher than normal level by somatostatin during hypoglycemia in insulin-dependent diabetic patients [1]. The effect of this dysregulated somatostatin on α -cells is to suppress glucagon secretion, which results in the insulin-dependent diabetic patient being unable to avoid or recover from hypoglycemia.

Stage of development

T1D Companies Landscape - DRAFT

Company OniX Summary

	<p>The document says that ZT-01 is in Phase 2 of development.</p> <p>Indication ZT-01 is being developed to prevent insulin-induced hypoglycemia in patients using insulin therapy.</p> <p>Other indications related to T1D The document did not mention any other indications for ZT-01 besides preventing insulin-induced hypoglycemia in patients with T1D.</p>
Zealand Pharma	<p>Asset: Zealand Pharma's main asset for the treatment of Type 1 Diabetes is Zegalogue (dasiglucagon), a glucagon analog.</p> <p>Mechanism of Action (MoA): Zegalogue is designed to rapidly increase blood glucose levels in people with diabetes experiencing severe hypoglycemia (low blood sugar).</p> <p>Stage of Development: Zegalogue has received FDA approval for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.</p> <p>Indication: Zealand Pharma has received FDA approval for Zegalogue for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes, including those with Type 1 Diabetes.</p> <p>Other Indications: In addition to Zegalogue for severe hypoglycemia in T1D, Zealand Pharma's pipeline also includes the following assets:</p> <ul style="list-style-type: none">• V-Go, an insulin delivery device for people with diabetes• Dapiglutide, a dual GLP-1/GCG receptor agonist in Phase 1 development for obesity and other metabolic disorders• Petrelintide, an amylin analog in preclinical development for obesity and other metabolic disorders• ZP6590, a GIP analog in preclinical development for obesity and other metabolic disorders
SAB Biotherapeutics	Asset:

T1D Companies Landscape - DRAFT

Company OniX Summary

SAB Biotherapeutics' lead asset for the treatment of Type 1 Diabetes is SAB-142, a fully-human anti-thymocyte globulin (ATG).

Mechanism of Action (MoA):

SAB-142 is designed to have a similar mechanism of action to rabbit ATG, which has been clinically validated in multiple trials for T1D. SAB-142 aims to directly target multiple immune cells involved in destroying insulin-producing pancreatic beta cells, potentially slowing down disease progression.

Stage of Development:

SAB-142 has recently been granted approval by Australian authorities to begin a first-in-human Phase 1 clinical study. SAB Biotherapeutics plans to pursue an investigational new drug application with the U.S. FDA.

Indication:

SAB Biotherapeutics is developing SAB-142 as a potential disease-modifying treatment for Type 1 Diabetes.

Other Indications:

The search results do not mention any other indications that SAB Biotherapeutics is pursuing with SAB-142 beyond Type 1 Diabetes.

Imcyse

Asset:

Imcyse's lead asset for the treatment of Type 1 Diabetes is their Imotope™ platform, which is designed to induce antigen-specific immune tolerance.

Mechanism of Action (MoA):

The Imotope™ platform aims to specifically target and modulate the immune cells responsible for the autoimmune attack on insulin-producing pancreatic beta cells in Type 1 Diabetes.

Stage of Development:

Imcyse's Imotope™ program for Type 1 Diabetes is currently in clinical-stage development.

Indication:

Imcyse is developing their Imotope™ platform as a potential disease-modifying treatment for Type 1 Diabetes.

Other Indications:

In addition to Type 1 Diabetes, Imcyse is also evaluating their Imotope™ platform in clinical and preclinical programs for other autoimmune diseases, including:

T1D Companies Landscape - DRAFT

Company OniX Summary

Entera Pharmaceuticals

- Multiple Sclerosis (clinical-stage)
- Neuromyelitis Optica (preclinical)
- Celiac Disease (preclinical)
- Rheumatoid Arthritis (preclinical)

The Imotope™ platform also has potential applications in allergies, graft-versus-host disease, Myasthenia Gravis, and preventing immunogenicity in gene therapies.

Asset:

Entera Pharmaceuticals' lead asset for the treatment of Type 1 Diabetes is Ent001, a first-in-class selective inhibitor.

Mechanism of Action (MoA):

Ent001 targets the TMEM219 ligand, IGFBP3, the levels of which are augmented in T1D and several other autoimmune diseases. Ent001 is designed to restore the endogenous pancreatic beta cell compartment.

Stage of Development:

Ent001 for the treatment of Type 1 Diabetes is currently in clinical development, with the company having initiated a Phase 1 clinical trial.

Indication:

Entera Pharmaceuticals is developing Ent001 as a potential disease-modifying therapy for the treatment of Type 1 Diabetes.

Other Indications:

In addition to Type 1 Diabetes, Entera Pharmaceuticals is also developing Ent001 and other first-in-class selective inhibitors for the treatment of autoimmune inflammatory diseases, such as Inflammatory Bowel Disease (IBD).

Connecting Ideas to Opportunities